Decompensated Cirrhosis Clinical Trial
Official title:
Coagulation Parameters With Albumin in Decompensated Cirrhosis (CoPA-D): An Open-label Randomized Control Trial
Albumin is commonly used plasma expander in patients of decompensated cirrhosis and has been found to have many beneficial effects, with few studies showing that maintenance of serum albumin levels above 3 g/dl has improved outcomes and mortality leading to widespread utilization in patients with cirrhosis of the liver. While 20% human albumin solution has been subject to in-depth analysis along several fronts, it's effects on coagulation parameters is unknown. With cirrhosis being a state of dysregulated clotting and bleeding, it is imperative to know the effects of such a widely used plasma expander on coagulation. The aim of this study is to evaluate the effects of albumin on coagulation parameters in patients of decompensated cirrhosis.
Aim and Objective: To study the effects of 20% human albumin infusions on coagulation parameters in patients with decompensated cirrhosis of the liver. Methodology: - Study population: All patients aged ≥ 18 years and ≤ 70 years admitted in Institute of Liver and Biliary Sciences, New Delhi with decompensated cirrhosis of any cause and S. Albumin ≤ 2.5 g/dl upon presentation and are giving written consent for participation in the study. - Study design - Single center, Open label, Randomized controlled trial - Study period - 1 year - Monitoring and assessment - - ABG prior to enrollment - Investigations - tests performed on Day 0, 1, 3, 5 and 7 or till discharge (whichever is earlier) - Routine: CBC, RFT, LFT, apTT, PT/INR, CXR - Coagulation parameter: ROTEM (EXTEM, FIBTEM), Fibrinogen - Inflammatory markers: ESR, CRP, IL-6, TNF-⍺ - Endothelial dysfunction: vWF, ADAMTS-13 - Cardiac function: NT-proBNP, PRA - 2 D Echo,PFT with DLCO will be done at 0,1 and 7 days. - Statistical Analysis: The data will be represented as mean±SD. The categorical data will be analysed using Chi-square test. The continuous data will be analysed by student T test, or Mann-Whitney test, whichever is applicable. Besides this, Cox regression will be applied to analyse the variables. For all tests, p≤ 0.05 will be considered statistically significant. - Adverse effects - Allergic reactions to albumin. - Features of symptomatic volume overload. - Stopping rule - Day 7, or discharge (whichever is earlier) - Allergic reaction to albumin - Features of symptomatic volume overload - Variceal bleeding - Requirement of coagulation correct Expected outcome of the project: Derangement of ROTEM in the group of patients receiving human albumin solution ;
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT01701687 -
Biomarkers for the Prognosis of Decompensated Alcoholic Liver Disease
|
N/A | |
Recruiting |
NCT05121870 -
Treatment With Human Umbilical Cord-derived Mesenchymal Stem Cells for Decompensated Cirrhosis
|
Phase 2 | |
Recruiting |
NCT05421351 -
Immune Profile, Neuronal Dysfunction, Metabolomics and Ammonia in Therapeutic Response of HE in ACLF
|
||
Not yet recruiting |
NCT05086536 -
Re-compensation and Its Clinical Characteristics in HBV Decompensated Cirrhosis
|
||
Recruiting |
NCT03820271 -
New Prognostic Predictive Models of Mortality of Decompensated Cirrhotic Patients Waiting for Liver Transplantation
|
N/A | |
Recruiting |
NCT06134544 -
Effect of IMO on Intestinal Microbiota Translocation in Cirrhosis
|
N/A | |
Recruiting |
NCT06223893 -
CirrhoCare- Using Smart-phone Technology to Enhance Care and Access to Treatment for Cirrhosis
|
N/A | |
Completed |
NCT02219477 -
A Study to Evaluate the Safety and Efficacy of Ombitasvir/Paritaprevir/Ritonavir and Dasabuvir With Ribavirin in Adults With Genotype 1 and Ombitasvir/Paritaprevir/Ritonavir With Ribavirin in Adults With Genotype 4 Chronic Hepatitis C Virus Infection and Decompensated Cirrhosis
|
Phase 3 | |
Recruiting |
NCT05734001 -
Rotational Thromboelastometry Versus Conventional Haemostatic Tests in Children With Decompensated Cirrhosis Undergoing Invasive Procedures.
|
N/A | |
Terminated |
NCT04775329 -
Primary Prophylaxis for Spontaneous Bacterial Peritonitis
|
Phase 2/Phase 3 | |
Recruiting |
NCT04422223 -
Prospective Cohort Study of Disease and Outcomes in Cirrhosis
|
||
Recruiting |
NCT02786017 -
Injectable Collagen Scaffold™ Combined With HUC-MSCs Transplantation for Patients With Decompensated Cirrhosis
|
Phase 1/Phase 2 | |
Completed |
NCT01326949 -
Transjugular Intrahepatic Portosystemic Shunt (TIPS) for Prevention of Variceal Rebleeding in Cirrhotic Patients With Portal Vein Thrombosis
|
N/A | |
Recruiting |
NCT06396897 -
Hospital @ Home Model of Care for Cirrhosis
|
||
Not yet recruiting |
NCT06306781 -
A Clinical Trial Evaluating the Safety, Tolerability, and Preliminary Efficacy of HCL001 Cell Injection (Homologous Allogeneic Hepatocytes) in Patients With Decompensated Cirrhosis
|
N/A | |
Recruiting |
NCT05227846 -
Human Umbilical Cord-derived Mesenchymal Stem Cells for Decompensated Cirrhosis (MSC-DLC-1)
|
Phase 1 | |
Active, not recruiting |
NCT03205345 -
Emricasan, a Caspase Inhibitor, for Treatment of Subjects With Decompensated NASH Cirrhosis
|
Phase 2 | |
Terminated |
NCT03462576 -
Companion Protocol for Methacetin Breath Test (MBT) in Conatus Protocol IDN-6556-17
|
||
Not yet recruiting |
NCT05224960 -
Human Umbilical Cord-derived Mesenchymal Stem Cells for Decompensated Cirrhosis (MSC-DLC-2)
|
Phase 2 | |
Terminated |
NCT04112199 -
A Study for Evaluation of BIV201 to Reduce Ascites and Complications in Patients With Cirrhosis and Refractory Ascites
|
Phase 2 |